Thomas Hawk posted a photo:
De mensenrechtenorganisatie vindt de uitspraken „niet alleen moreel verwerpelijk”, schrijft ze, „maar [ze] zetten naar onze mening aan tot geweld tegen Palestijnen.”
/s3/static.nrc.nl/wp-content/uploads/2026/05/14210427/140526VER_2033742318_markus.jpg)
The AI systems approved for Ontario healthcare providers routinely missed critical details, inserted incorrect information, and hallucinated content that neither patients nor clinicians mentioned, according to a provincial audit of 20 approved vendors’ systems. The findings come from the Office of the Auditor General of Ontario, Canada, and are included in a larger report about the state of AI usage by public services in the province. They specifically address the AI Scribe program, the Ontario Ministry of Health initiated for physicians, nurse practitioners, and other healthcare professionals across the broader health sector. As part of the procurement process, officials conducted evaluations using simulated doctor-patient recordings. Medical professionals then reviewed the original recordings alongside the AI-generated notes to evaluate their accuracy. What they found was, frankly, shocking for anyone concerned about the accuracy of AI in critical situations. Nine out of 20 AI systems reportedly “fabricated information and made suggestions to patients' treatment plans” that weren’t discussed in the recordings. According to the report, evaluators spotted potentially devastating incorrect information in the sample reports, such as no masses being found, or patients being anxious, even though these things were never discussed in the recordings. Twelve of the 20 systems evaluated inserted incorrect drug information into patient notes, while 17 of the systems “missed key details about the patients’ mental health issues” that were discussed in the recordings. Six of the systems “missed the patients’ mental health issues fully or partially or were missing key details,” per the report. OntarioMD, a group that offers support for physicians in adopting new technologies and was involved in the AI Scribe procurement process, has recommended that doctors manually review their AI notes for accuracy, but the report notes there’s no mandatory attestation feature in any of the AI Scribe-approved systems. Bad evaluations don’t help, either AI systems making mistakes isn’t exactly shocking. As we’ve reported previously, consumer-focused AI has a tendency to provide bad medical information to users, and some studies have found large language models failed to produce appropriate differential diagnoses in roughly 80 percent of tested cases. But the tools evaluated here are for doctors, not consumers, and such poor performance necessitates explanation. A good portion of the report blames how the systems were evaluated. According to the report, the weight given to various categories of AI Scribe performances was wonky. While 30 percent of a platform’s evaluation score depended solely on whether they had a domestic presence in Ontario, the accuracy of medical notes contributed only 4 percent to the total score. Bias controls accounted for only 2 percent of the total evaluation score; threat, risk, and privacy assessments counted for another 2 percent; and SOC 2 Type 2 compliance contributed an additional 4 percentage points. In other words, criteria tied to accuracy, bias controls, and key security and privacy safeguards made up only a small portion of the total evaluation score for the AI Scribe systems. “Inaccurate weightings could result in the selection of vendors whose AI tools may produce inaccurate or biased medical records or lack adequate protection to safeguard sensitive personal health information,” the report said of the scoring regime. The Register reached out to the Ontario Health Ministry for its take on the report, and whether it was going to conform to its recommendations for the AI Scribe program, but we didn’t immediately hear back. A spokesperson for the Ministry told the CBC on Wednesday that more than 5,000 physicians in Ontario are participating in the AI Scribe program and there have been no known reports of patient harms associated with the technology. ®
Longtime Slashdot reader schwit1 shares a report from CNBC: The U.S. has cleared around 10 Chinese firms to buy Nvidia's second-most powerful AI chip, the H200, but not a single delivery has been made so far, three people familiar with the matter said, leaving a major technology deal in limbo as CEO Jensen Huang seeks a breakthrough in China this week. [...] Before U.S. export curbs tightened, Nvidia commanded about 95% of China's advanced chip market. China once accounted for 13% of its revenue, and Huang has previously estimated the country's AI market alone would be worth $50 billion this year.
The U.S. Commerce Department has approved around 10 Chinese companies including Alibaba, Tencent, ByteDance and JD.com to purchase Nvidia's H200 chips, according to the sources, who spoke on condition of anonymity due to the sensitivity of the matter. A handful of distributors including Lenovo and Foxconn have also been approved, they said. Buyers are permitted to purchase either directly from Nvidia or through those intermediaries and each approved customer can purchase up to 75,000 chips under the U.S. licensing terms, two of them said.
Despite U.S. approval, deals have stalled, as Chinese firms pulled back after guidance from Beijing, one source said. The shift in China was partly triggered by changes on the U.S. side, though exactly what changed remains unclear, the person added. In Beijing, pressure is mounting to block or tightly vet the orders, a separate fourth source said. Commerce Secretary Howard Lutnick echoed that view, telling a Senate hearing last month that "the Chinese central government has not let them, as of yet, buy the chips, because they're trying to keep their investment focused on their own domestic industry."
The U.S. Commerce Department has approved around 10 Chinese companies including Alibaba, Tencent, ByteDance and JD.com to purchase Nvidia's H200 chips, according to the sources, who spoke on condition of anonymity due to the sensitivity of the matter. A handful of distributors including Lenovo and Foxconn have also been approved, they said. Buyers are permitted to purchase either directly from Nvidia or through those intermediaries and each approved customer can purchase up to 75,000 chips under the U.S. licensing terms, two of them said.
Despite U.S. approval, deals have stalled, as Chinese firms pulled back after guidance from Beijing, one source said. The shift in China was partly triggered by changes on the U.S. side, though exactly what changed remains unclear, the person added. In Beijing, pressure is mounting to block or tightly vet the orders, a separate fourth source said. Commerce Secretary Howard Lutnick echoed that view, telling a Senate hearing last month that "the Chinese central government has not let them, as of yet, buy the chips, because they're trying to keep their investment focused on their own domestic industry."
Read more of this story at Slashdot.
Niets fijners dan een weekeinde Antwerpen en al helemaal tijdens het Antwerp Art Weekend, dat tot en met zondag gehouden wordt. Op 88 adressen, van de slicke galeries op Zuid en tijdelijk gevulde kantoorpanden op [Meer...]